Product Information
ORM-15341 is a new anticancer drug that has shown safety and efficacy in a phase I clinical study. The compound inhibits the growth of prostate cancer cells by inhibiting the function of DNA topoisomerase IIα, which is an enzyme that maintains the integrity of DNA. This drug is structurally similar to doxorubicin, but has a long half-life and better pharmacokinetic properties. The long-term safety of ORM-15341 was evaluated in patients with advanced solid tumors receiving continuous treatment for up to 12 months without any significant toxicity. A single dose pharmacokinetic study showed this compound had a high bioavailability after oral administration and low clearance rates. ORM-15341 has been validated in vitro using human tissue samples and shown to have good safety profile. This drug has also been tested in a phase I clinical study for its anticancer activity and pharmacokinetics.
Chemical properties
Technical inquiry about: 3D-XBC53733 ORM-15341
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
